Insider Selling: Medpace (NASDAQ:MEDP) CEO Sells $1,494,368.70 in Stock

by · The Cerbat Gem

Medpace Holdings, Inc. (NASDAQ:MEDP – Get Free Report) CEO August Troendle sold 2,410 shares of the company’s stock in a transaction dated Monday, September 28th. The stock was sold at an average price of $620.07, for a total transaction of $1,494,368.70. Following the sale, the chief executive officer directly owned 386,892 shares of the company’s stock, valued at $239,900,122.44. This represents a 0.62% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink.

Medpace Trading Up 1.0%

Medpace stock traded up $6.17 during trading hours on Tuesday, reaching $622.11. 249,674 shares of the stock were exchanged, compared to its average volume of 331,499. Medpace Holdings, Inc. has a twelve month low of $373.00 and a twelve month high of $677.90. The company has a market cap of $17.36 billion, a P/E ratio of 36.47, a price-to-earnings-growth ratio of 2.76 and a beta of 1.15. The stock has a 50 day moving average of $596.41 and a two-hundred day moving average of $517.30.

Medpace (NASDAQ:MEDP – Get Free Report) last issued its earnings results on Wednesday, July 22nd. The company reported $4.25 EPS for the quarter, beating the consensus estimate of $3.98 by $0.27. Medpace had a net margin of 17.67% and a return on equity of 110.15%. The company had revenue of $707.33 million during the quarter, compared to analysts’ expectations of $689.51 million. During the same period in the previous year, the company earned $3.10 EPS. The business’s revenue for the quarter was up 17.2% compared to the same quarter last year. Medpace has set its FY 2026 guidance at 17.250-17.950 EPS. On average, analysts expect that Medpace Holdings, Inc. will post 17.54 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Medpace

Hedge funds have recently modified their holdings of the company. BlackRock Inc. acquired a new position in Medpace in the 2nd quarter worth about $1,323,047,000. Wasatch Advisors LP boosted its stake in shares of Medpace by 19.4% during the first quarter. Wasatch Advisors LP now owns 773,931 shares of the company’s stock valued at $371,634,000 after purchasing an additional 125,625 shares in the last quarter. State Street Corp grew its holdings in shares of Medpace by 4.2% during the second quarter. State Street Corp now owns 710,895 shares of the company’s stock worth $376,483,000 after purchasing an additional 28,666 shares during the last quarter. Geode Capital Management LLC grew its holdings in shares of Medpace by 3.8% during the fourth quarter. Geode Capital Management LLC now owns 667,298 shares of the company’s stock worth $374,836,000 after purchasing an additional 24,625 shares during the last quarter. Finally, Renaissance Technologies LLC grew its holdings in shares of Medpace by 8.3% during the first quarter. Renaissance Technologies LLC now owns 504,668 shares of the company’s stock worth $242,337,000 after purchasing an additional 38,760 shares during the last quarter. Institutional investors and hedge funds own 77.98% of the company’s stock.

Analysts Set New Price Targets

Several research firms have weighed in on MEDP. BMO Capital Markets upped their target price on Medpace from $400.00 to $600.00 and gave the stock a “market perform” rating in a research note on Friday, July 24th. Jefferies Financial Group reiterated a “hold” rating on shares of Medpace in a research note on Monday, September 14th. Royal Bank Of Canada boosted their price target on Medpace from $484.00 to $692.00 and gave the stock an “outperform” rating in a report on Friday, July 24th. Mizuho upped their price objective on Medpace from $586.00 to $665.00 and gave the stock an “outperform” rating in a research report on Friday, July 24th. Finally, Truist Financial raised their price objective on Medpace from $462.00 to $609.00 and gave the company a “hold” rating in a research note on Friday, July 24th. Three research analysts have rated the stock with a Buy rating and nine have issued a Hold rating to the company. According to data from MarketBeat.com, Medpace has an average rating of “Hold” and an average price target of $595.20.

Get Our Latest Analysis on MEDP

About Medpace

(Get Free Report)

Medpace Holdings, Inc is a contract research organization (CRO) that provides clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports sponsors throughout the product development process, from early planning and protocol design through clinical trials, regulatory submission and post-marketing activities.

Its services include clinical trial management, clinical monitoring, biostatistics, data management, medical writing, pharmacovigilance and regulatory consulting.

See Also